Showing results (241-250 of 866) with videos related to
Sort By:
Pageof 87
The Journal of Biological Chemistry|April 19, 2003
Evidence that both exosites on thrombin participate in its high affinity interaction with fibrinCaroline H Pospisil, Alan R Stafford, James C Fredenburgh, et al.The Journal of Biological Chemistry|December 7, 2007
Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complexJames C Fredenburgh, Alan R Stafford, Beverly A Leslie, et al.Circulation Research|September 18, 2012
Translational success stories: development of direct thrombin inhibitorsMichiel Coppens, John W Eikelboom, David Gustafsson, et al.Journal of the American College of Cardiology|August 6, 2021
Factor XI Inhibition to Uncouple Thrombosis From Hemostasis: JACC Review Topic of the WeekCharles Hsu, Edward Hutt, Daniel M Bloomfield, et al.Chest|February 9, 2012
Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesDavid A Garcia, Trevor P Baglin, Jeffrey I Weitz, et al.Seminars in Thrombosis and Hemostasis|March 23, 2004
Oncogenes as regulators of tissue factor expression in cancer: implications for tumor angiogenesis and anti-cancer therapyJoanne L Yu, Linda May, Petr Klement, et al.Biochemistry|March 9, 2007
In the presence of phospholipids, glycosaminoglycans potentiate factor Xa-mediated protein C activation by modulating factor Xa activitySimon J McRae, Alan R Stafford, James C Fredenburgh, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|March 7, 2009
Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in ratsJi Zhou, Linda May, Peng Liao, et al.The Canadian Journal of Cardiology|August 11, 2018
Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of DabigatranJeffrey I Weitz, Karen M Earl, Kori Leblanc, et al.Thrombosis Research|September 28, 2010
Antithrombotic activity of the novel oral anticoagulant, Tecarfarin [Sodium 3-[4-((1,1,1,3,3,3-hexafluoro-2-methylpropan-2-yloxy) carbonyl) benzyl]-2-oxo-2H-chromen-4-olate] in animal modelsS Scott Bowersox, Daniel Canafax, Pascal Druzgala, et al.Pageof 87